menu
    • menu

    Company profile for Actym Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Actym Therapeutics is based in Berkeley, California and was founded in 2017 by Christopher Thanos Ph.D., Laura Hix Glickman, Ph.D., and Amit Kumar, Ph.D. The company has developed a microbial-based immunotherapy platform called STACT (S. Typhimurium Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed i...
    Actym Therapeutics is based in Berkeley, California and was founded in 2017 by Christopher Thanos Ph.D., Laura Hix Glickman, Ph.D., and Amit Kumar, Ph.D. The company has developed a microbial-based immunotherapy platform called STACT (S. Typhimurium Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payloads are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Actym TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    626 Bancroft Way Suite A Berkeley, CA 94710
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.actymthera.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actym Therapeutics Announces Issuance of US Patents
    Actym Therapeutics Announces Issuance of US Patents

    02 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250602896710/en/Actym-Therapeutics-Announces-Issuance-of-US-Patents

    BUSINESSWIRE
    02 Jun 2025
    Share Share
    Actym Therapeutics Expands Management Team for Product Pipeline
    Actym Therapeutics Expands Management Team for Product Pipeline

    25 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/actym-therapeutics-expands-management-team-with-key-appointments-to-build-product-pipeline-and-advance-clinical-development-strategies-302181468.html

    PR NEWSWIRE
    25 Jun 2024
    Share Share
    Actym Gets IND Clearance For Phase 1 Trial Of ACTM-838 In Solid Tumors
    Actym Gets IND Clearance For Phase 1 Trial Of ACTM-838 In Solid Tumors

    30 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/actym-therapeutics-announces-ind-clearance-for-phase-1-clinical-trial-investigating-lead-program-actm-838-in-patients-with-solid-tumors-302159288.html

    PR NEWSWIRE
    30 May 2024
    Share Share
    Actym Therapeutics Appoints Thomas Smart as CEO
    Actym Therapeutics Appoints Thomas Smart as CEO

    24 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/actym-therapeutics-appoints-thomas-smart-as-ceo-302125751.html

    PR NEWSWIRE
    24 Apr 2024
    Share Share
    Actym to Present Preclinical Data on Clinical Candidate ACTM-838
    Actym to Present Preclinical Data on Clinical Candidate ACTM-838

    03 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/actym-to-present-preclinical-data-on-clinical-candidate-actm-838-at-38th-sitc-annual-meeting-301977120.html

    PR NEWSWIRE
    03 Nov 2023
    Share Share
    Actym Appoints Steven Vicik as Chief Technical Officer
    Actym Appoints Steven Vicik as Chief Technical Officer

    26 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/actym-appoints-steven-vicik-as-chief-technical-officer-301968742.html

    PR NEWSWIRE
    26 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search